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Abstract
Background: The postoperative cognitive function is impaired in elderly patients after general anaesthesia. The fast
recovery after xenon anaesthesia was hypothesized to be advantageous in this scenario. We compared early
postoperative cognitive function after xenon and sevoflurane anaesthesia in this study.
Methods: The study was approved by the local ethics committee and written informed consent was obtained
from each patient. Patients aged 65-75 years (ASA I-III) scheduled for elective surgery (duration 60-180 min) were
enrolled. Investigators performing cognitive testing and patients were blinded towards allocation to either xenon
or sevoflurane anaesthesia. Baseline assessment of cognitive function was carried out 12-24 h before the operation.
The results were compared to follow-up tests 6-12 and 66-72 h after surgery. Primary outcome parameter was the
subtest “Alertness” of the computerized Test of Attentional Performance (TAP). Secondary outcome parameters
included further subtests of the TAP, several Paper-Pencil-Tests, emergence times from anaesthesia, modified
Aldrete scores and patients’ well-being.
Results: 40 patients were randomized and equally allocated to both groups. No significant differences were found
in the TAP or the Paper-Pencil-Tests at 6-12 and 66-72 h after the operation. All emergence times were faster after
xenon anaesthesia. The modified Aldrete scores were significantly higher during the first hour in the xenon group.
No difference in well-being could be detected between both groups.
Conclusions: The results show no difference in the incidence of postoperative cognitive dysfunction (POCD) after
xenon or sevoflurane anaesthesia. Emergence from general anaesthesia was faster in the xenon group.
Introduction
Age is a known risk factor for postoperative cognitive
dysfunction (POCD) after cardiac and non-cardiac sur-
gery [1-3]. Up to 41% of patients aged 60 years and
older are affected by POCD and exposed to an increased
risk of death within the first 12 months after major non-
cardiac surgery [1].
Although a growing number of researchers are con-
centrating on POCD [4], no significant progress can be
seen in the prevention of POCD.
The noble gas xenon offers good haemodynamic stabi-
lity [5-10] and favours rapid recovery from anaesthesia
[11,12], both of which have been hypothesized to be ben-
eficiary in the reduction of POCD [13-15]. Xenon is a
safe anaesthetic agent [12,16,17] which has been
approved for clinical use in Germany (ASA I-III patients)
since 2005 and in Europe (ASA I-II patients) since 2007
[18]. Its remarkable potential of neuronal protection has
been demonstrated in several in vivo and in vitro models
of ischemic and traumatic neuronal injury [19-24].
This study was conducted to investigate early post-
operative cognitive function in elderly patients after gen-
eral anaesthesia, hypothesizing a positive influence by
use of xenon compared to sevoflurane.
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Confirmation of this hypothesis would be an impor-
tant step towards establishing strategies for the preven-
tion and reduction of POCD.
Methods
The study was designed as a prospective, inpatient, dou-
ble-blinded, randomized, controlled trial. It was con-
ducted at the University Hospital Aachen, Germany after
obtaining approval from the local ethics committee.
Random assignment of the patients to either the sevo-
flurane or xenon anaesthesia group was achieved by
using a computer-generated allocation sequence. Study
investigators and patients were blinded in terms of
group assignment. It was not feasible to blind the anaes-
thetist due to the different administration methods of
the anaesthetics.
Primary outcome parameter of this study was the cog-
nitive function, which was assessed with the subtest
“Alertness” of the computerized Test for Attentional
Performance (TAP, Version 1.7; Psytest, 2002).
As described previously, several other subtests of the
TAP and additional Paper-Pencil-Tests were selected to
monitor a wide spectrum of cognitive functions
[13,15,25,26].
The set of Paper-Pencil-Tests included the Digit-Sym-
bol-Substitution-Test (DSST), Recall of Digit Span (DS)
and the Trail Making Tests A and B [27-29].
Anxiety and Depression were measured with the Well-
being Test Bf-S and the short form of the Spielberger
State-Trait Anxiety Inventory (STAI) [30,31].
Secondary outcome parameters were the emergence
times from anaesthesia and the modified Aldrete scores
recorded in the post-anaesthetic care unit (PACU) [32].
Levels of vigilance, well-being and energy were also
assessed in the PACU.
Patients were assessed for eligibility and gave informed
written consent to participating in the trial. A total of 40
patients, aged 65-75 years, and ASA status I-III were
enrolled in this study. Patients were excluded from the
trial in case of diabetes mellitus, congestive heart failure,
adrenal insufficiency, reduced renal and/or hepatic func-
tion, chronic alcohol or drug abuse, disabling neuropsy-
chiatric disorders, increased intracranial pressure, a
history of stroke, cardiopulmonary resuscitation or brain
trauma within the past 12 months, anaphylactic reac-
tions to anaesthetics, legal incapacity, a lack of coopera-
tion or the need for emergency operations.
The elective surgical operations under general anaes-
thesia were planned for 60-180 min and scheduled in
urology, gynaecology, neurosurgery, trauma, ENT,
orthopaedics and abdominal surgery. Neurosurgery was
limited to interventions on the spine.
Management of anaesthesia followed standardised
instructions, identical for both groups. Following a 3
min period of preoxygenation (100% O2), anaesthesia
was induced through a single slow i.v. injection of pro-
pofol (2 mg kg-1) and simultaneous infusion of remifen-
tanil (0.5 μg kg-1 over 60 s). Facilitation of tracheal
intubation was achieved with rocuronium (0.6 mg kg-1).
Standard monitoring of the patients included pulse
oximetry, three-lead ECG, non-invasive blood pressure,
temperature (AS/3 monitor, GE Datex-Ohmeda, Hel-
sinki, Finland), bispectral index monitoring (BIS Model
A 2000®, Software Version 2.21, Aspect Medical Sys-
tems, Boston, MA, USA) and end-tidal concentrations
of oxygen, carbon dioxide and anaesthetic gases. All
parameters were recorded at fixed intervals of 5 min.
Maintenance of anaesthesia was achieved by either
xenon or sevoflurane. Administration of sevoflurane was
started with age-adapted equipotent MAC values of 1
with 1.1-1.4 vol% in 30% oxygen (Cato®, Draeger,
Lübeck, Germany) [33].
Xenon was started at 60% xenon in 30% oxygen and
administered with a close circuit anaesthesia machine
(Physioflex®, Draeger, Lübeck, Germany) using a soft-
ware modification to allow the reduction of xenon con-
sumption under minimal flow conditions. The
inspiratory concentration of xenon was measured with
an automatically calibrated thermo-conductive device in
the anaesthesia machine (± 3 vol% accuracy).
Air Liquide Deutschland GmbH (Business Unit, Kre-
feld, Germany) provided xenon of medical quality in
steel cylinders for this study.
Infusion of remifentanil was carried out at a base rate
of 0.15 μg kg-1 min-1 and titrated according to clinical
needs. The remifentanil infusion was increased based on
haemodynamic (heart rate, systolic arterial blood pres-
sure), somatic (swallowing, movement) and autonomic
sings (flushing, sweating, salivating) at 0.05 μg kg-1 min-
1 increments until symptoms were resolved.
Standard treatment of blood loss and fluid replace-
ment strategy were used if necessary.
The standardised instructions included the administra-
tion of piritramide 0.05 μg kg-1 twenty minutes before
the estimated end of surgery as well as a short infusion
of metamizole 15 mg kg-1, both as part of the post-
anaesthetic pain management.
Inhaled anaesthetics were reduced to 0.5 MAC ten
minutes before the estimated end of the intervention.
Discontinuation of anaesthesia required completion of
all surgical tasks (including bandaging) and complete
recovery from neuromuscular block (TOF-Watch SX®,
Organon Teknika, Eppelheim, Germany).
The return of spontaneous breathing was aided by
allowing a rise of end-expiratory carbon dioxide levels
up to 6.6 kPa.
Extubation of the patients’ tracheas required full
recovery of the upper airway reflexes, sufficient
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spontaneous breathing (>8 breaths min-1, SaO2 > 95%
with FiO2 at 100%) and haemodynamic stability.
Starting with the discontinuation of the anaesthetic, a
blinded investigator recorded the emergence times from
anaesthesia as part of the secondary outcome para-
meters. This included the time to extubation, time to
awakening (eyes open), time to basic verbal command
(squeeze investigator’s hand) and time to return of
orientation (date, time, place), all determined at 20 s
intervals.
All patients were transferred from the operating room
to the post-anaesthetic care unit for recovery. The study
investigator recorded the modified 10-point scaled
Aldrete scores at 5, 15, 30, 45, 60 min and at discharge
from the PACU.
Pain level, dosage of postoperative analgesics, inci-
dence of nausea and vomiting, use and dosage of antie-
metics, as well as vigilance, well-being and energy were
rated and recorded at the same intervals. Pain manage-
ment included piritramide 0.05 mg kg-1 if VAS for pain
was rated >3.
The primary outcome parameter, as well as the addi-
tional measures of cognitive function, was recorded for
each patient during three predetermined time intervals.
Baseline testing was completed 12-24 h preoperatively.
These tests were repeated in the same order between 6-
12 h and again after 66-72 h postoperatively.
All instructions on how to perform the tests were given
in a standard way by a blinded investigator to ensure uni-
form collection of data. The assessment took place in a
quiet room, reducing outside disturbances. The tests
were completed by the patients in about 45-60 min.
The TAP consists of low complexity tasks, using easily
distinguishable stimuli that demand a simple motor
response from the patient. It is designed to reduce inter-
fering factors, such as sensory and motor failure and
disturbances of speech or memory. The test batteries
consisted of the subtests for Alertness, Visual Scanning,
Divided Attention, Reaction Change and Working Mem-
ory. All tests were administered at the highest level of
difficulty.
The two groups were compared in terms of test per-
formance normalized to the preoperative baseline
assessment and in terms of the number of patients with
a decrease of 20% or more in test performance. A
patient with a 20% decrease in at least 20% of all tests
was considered to be suffering from POCD [15,34].
During the 6-12 h postoperative assessment, patients
were asked to evaluate the anaesthesia and questioned
whether they would choose the same procedure for
further operations.
Statistical analysis was performed using SPSS 16.0
(SPSS Inc., Chicago, IL, USA); all figures were generated
with GraphPad PRISM® (GraphPad Software Inc., La
Jolla, CA, USA). Categorical data were tested with the
two-tailed Fisher’s exact test and are presented as num-
bers and per cents of total. Parametric data were ana-
lysed with one-way ANOVA and are given accordingly
as means and standard error of the means, means and
95% confidence intervals, means and standard deviation
or means and range.
The sample size of this study was calculated for the pri-
mary outcome parameter (subtest “Alertness” of the TAP)
with a significance level of a = 0.05 and a power of b =
0.8, considering a difference of 20% as relevant. Mean
values and standard deviations of the primary outcome
parameter were taken from the TAP databases (patients ≥
65 years; n = 416; 242 ± 60 ms). The trial size was calcu-
lated with n = 18 and then determined with n = 20
patients per group to compensate for possible dropouts.
The power calculation was performed with nQuery Advi-
sor®, Version 7.0 (Statistical Solutions, Saugus, MA, USA).
Results
A total of 40 patients were included in this study, equally
distributed between the two groups. 39 patients under-
went baseline testing prior to the operation and 37
patients completed the 6-12 h postoperative assessment
(18 from the sevoflurane and 19 from the xenon group),
while the 66-72 h assessment was completed by 18 and
14 patients (32 in total). The reasons for drop-outs
included refusal of testing and discharge from the hospi-
tal previous to assessment and are shown in Figure 1.
The study groups were comparable regarding the dis-
tribution of patients’ age, weight and height, level of edu-
cation, gender, Apfel-Score and ASA status (Table 1).
Baseline-testing was scheduled 12-24 h prior to the
operation and all patients underwent testing within that
time-frame. The mean time-point of baseline-testing
was at 18:33 (18:12-18:54) in the sevoflurane group and
at 17:54 (17:30-18:18) in the xenon group, resulting in a
difference between the two groups (Table 2).
Duration of anaesthesia as well as the type of surgery
did not differ between groups. The average end-tidal
concentration of volatile anaesthetics for maintenance of
anaesthesia was 1.18% (0.2) for sevoflurane and 53%
(5.2) for xenon. Consumption of remifentanil (intrao-
perative) and piritramide (intra- and postoperative) were
comparable between the two groups.
All recovery-times recorded during the emergence
from anaesthesia showed a difference between groups
regarding “time to open eyes”, “time to react on
demand”, “time to extubation” and “time to time and
spatial orientation” with a significantly faster recovery in
the xenon group (Table 3).
There was no significant difference in the length of
stay in the PACU (Table 2). The modified Aldrete
scores recorded in the PACU were significantly higher
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in the xenon group from arrival until 60 min, while
results at discharge were comparable. The following
other scores from the PACU were in favour of xenon:
vigilance at 5 min; well-being at 30 and 45 min and
energy during the complete period (Table 4).
Both postoperative assessments were performed at
similar time points (Table 2). The results of patients’
self-evaluation of the anaesthesia were homogenous in
both groups.
There were no differences between the two groups at
the 12-24 h preoperative baseline assessment of cogni-
tive function with the TAP and the Paper-Pencil-Tests.
The postoperative tests at 6-8 and 66-72 h were normal-
ized to the preoperative baselines.
The subtest “Alertness” as the primary outcome para-
meter of this study, as well as all other subtests of the
TAP and the Paper-Pencil-Tests, did not show a signifi-
cant difference between the two groups (Figures 2 + 3).
Assessed for Eligibility 
(n=40)
Randomized 
(n=40)
Xenon Group (n=19)
One patient withdrew the 
consent
Baseline Testing (n=19)
6-12h Follow-up Assessment (n=18)
Received allocated Intervention (n=18)
One patient did not receive the allocated 
intervention
Received allocated Intervention (n=20)
6-12h Follow-up Assessment (n=19)
One patient refused testing
66-72h Follow-up Assessment (n=18)
One patient refused testing
Sevoflurane Group 
(n=20)
66-72h Follow-up Assessment (n=14)
Three patients refused testing and one patient was 
discharged before the third assessment
Baseline Testing (n=20)
Figure 1 Flowchart. Flowchart showing patients during the course of the trial, including reasons for dropouts.
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The number of patients with a decline of 20% or more
in test performance is shown for each test in Table 5.
The Trail Making Test A conducted at 66-72 h was the
only test with a significant difference, while all other
Paper-Pencil-Tests and the TAP showed no difference
between the groups (Table 5).
Postoperative cognitive dysfunction was defined as a
20% decline in 20% of all tests (TAP and Paper-Pencil-
Tests combined) [15,34]. The incidence was comparable
between the two groups at the postoperative evaluations
at 6-8 h (xenon 39%, sevoflurane 32%; p = 0.737) and
66-72 h (xenon 29%, sevoflurane 44%; p = 0.471).
A decrease in patients’ well-being was measured with
the Bf-S in both groups 6-12 h after the operation,
while closely returning to baseline values at the second
postoperative evaluation (Figure 3). Anxiety assessed
with the STAI showed a continuous decrease during
both postoperative assessments in all patients (Figure 3).
Discussion
We compared early cognitive function in elderly patients
after xenon or sevoflurane anaesthesia in this study.
None of the applied tests detected a significant differ-
ence in the incidence of POCD between the xenon and
the sevoflurane group.
Selection of the correct testing instruments is essen-
tial, since the definition of POCD and its measurement
varies in previous studies [4,35]. The TAP is a com-
monly used device to measure attention (further infor-
mation: http://www.psytest.net) [13,15]. In this study, we
used its subtests Alertness, Divided Attention, Visual
Scanning, Working Memory and Reaction Change,
along with several Paper-Pencil-Tests.
Repeated postoperative assessments might result in a
learning effect. The retest reliability of the TAP was
shown before [25], although our test intervals were much
shorter in this study. The intervals were identical with
Table 1 Patient data
Sevoflurane
(n = 20)
Xenon
(n = 19)
P-value
Age (years) 70 (65-75) 69 (65-75) 0,441
Height (cm) 169 (9) 171 (6) 0,461
Weight (kg) 78 (12) 78 (12) 0,906
Gender male/female 11/9 13/6 0,514
Education <12/≥12 yr 17/3 15/4 0,469
ASA I/II/III 1/13/6 0/13/6 0,614
Apfel-Score 1/2/3/4 8/8/3/1 9/8/2/0 0,745
Age is presented as mean (range). Height and weight of the patients are
given as mean (SD). Gender, school education <12 or ≥12 years, ASA
classification and Apfel-Score are presented in total numbers.
Table 2 Anaesthesia data and times of testing
Sevoflurane Xenon P-value
Average gas concentration (%) 1,18 (0,2) 53 (5,2) -
Type of surgery
Trauma 3 (15) 2 (10,5) 0,967
Orthopaedics 2 (10) 2 (10,5)
ENT 1 (5) 1 (5,3)
Gynaecology 2 (10) 3 (15,8)
Urology 7 (35) 7 (36,8)
Neurosurgery 4 (20) 4 (21,1)
Abdominal surgery 1 (5) 0 (0)
Anaesthesia time (min) 151 (121-181) 164 (121-206) 0,606
PACU time (min) 65 (52-79) 78 (64-93) 0,186
Remifentanil consumption (μg/kg/min) 0,13 (0,05) 0,16 (0,04) 0,065
Intraoperative piritramide (mg) 5,9 (2,4) 5,6 (1,2) 0,364
Postoperative piritramide (mg) 7,9 (4,7) 5,8 (4,2) 0,625
Preoperative assessment (hh:min) 18:33 (18:12-18:54) 17:54 (17:30-18:18) 0,016
6-12 h postop. assessment (hh:min) 15:42 (13:42-17:42) 15:15 (13:10-17:21) 0,746
66-72 h postop. assessment (hh:min) 15:39 (13:51-17:27) 15:36 (14:12-17:00) 0,969
Average anaesthetic gas concentration is displayed as mean (SD). Type of surgery is presented in number (% of total). Anaesthesia and PACU times are given as
means with the upper and lower 95% confidence interval in parentheses. Remifentanil values and intra- and postoperative consumption of piritramide are
presented as means (SD). Time points of pre- and postoperative testing are shown in hours and minutes with the upper and lower 95% confidence interval in
parentheses.
Table 3 Emergence from anaesthesia
Time Sevoflurane Xenon P-value
to open eyes 8,5 (6,7-10,3) 4,6 (3,8-5,5) ≤0,001
to react on demand 8,0 (6,1-9,9) 4,6 (3,5-5,7) 0,004
to extubation 8,3 (6,5-10,1) 4,6 (3,8-5,5) 0,001
to time and spatial orientation 10,3 (8,7-11,8) 7,6 (6,1-9,1) 0,014
All times are given in minutes as mean with lower and upper 95% confidence
interval in parentheses.
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those suggested by previous studies [13,15]. Alternating
equivalent versions of the Paper-Pencil-Tests were used if
available, in an effort to minimize learning effects [4,35].
The subtest “Alertness” of the TAP as the primary
outcome parameter did not show a significant difference
in test performance between the two groups. Additional
subtests of the TAP enabled us to monitor a wider spec-
trum of cognitive functions, but also showed comparable
results. The applied Paper-Pencil-Tests detected no dif-
ference in test performance.
The number of patients with a decrease of 20% or
more was comparable for each test between the two
groups, with exemption of the Trail Making Test A con-
ducted at 66-72 h postoperatively. The relevance of this
finding is limited due to the fact that this test is only
one of twelve aspects considered in our calculation of
actual postoperative cognitive dysfunction.
The over-all incidence of POCD was high, but com-
parable between the two groups at both postoperative
evaluations (6-8 h: xenon 39%, sevoflurane 32%; 66-72
h: xenon 29%, sevoflurane 44%). Other studies found
similar figures, but direct comparison with our study is
limited due to the use of different tests and investigated
substances [15,26,36].
We were able to show significant differences within
each group in comparison to the preoperative baseline
in some tests, but could not detect such differences
between the two groups.
These findings are in accordance with previous studies
[4,13,15,26]. None of the investigated anaesthesia regi-
mens showed a significant benefit in terms of reduced
incidence and severity of POCD. However all of these
studies are limited in their power.
Preoperative testing is crucial, since all calculations are
based on these results. The pending operation can pose
a stress factor for the patients and hence possibly influ-
ence the test results. We chose a 12-24 h period prior
to the operation for our assessment in an attempt to
limit these effects in comparison to an assessment
directly before premedication was given as used by
Table 4 PACU data
Sevoflurane Xenon P-value
Aldrete A 8,9 (0,9) 9,7 (0,6) 0,007
Aldrete 5 8,9 (1,0) 9,7 (0,5) 0,005
Aldrete 15 9,1 (1,0) 9,7 (0,6) 0,023
Aldrete 30 9,2 (1,1) 9,8 (0,3) 0,028
Aldrete 45 9,1 (1,1) 9,9 (0,3) 0,01
Aldrete 60 9,1 (1,1) 9,9 (0,4) 0,034
Aldrete D 9,8 (0,4) 9,7 (0,7) 0,88
Vigilance A (A/T/S) 7/12/1 (35/60/5) 13/5/0 (72/287/0) 0,061
Vigilance 5 (A/T/S) 9/11/0 (45/55/0) 15/3/0 (83/17/0) 0,014
Vigilance 15 (A/T/S) 10/10/0 (50/50/0) 13/5/0 (72/28/0) 0,162
Vigilance 30 (A/T/S) 12/8/0 (60/40/0) 14/4/0 (78/22/0) 0,239
Vigilance 45 (A/T/S) 9/7/0 (56/44/0) 13/4/0 (76/24/0) 0,218
Vigilance 60 (A/T/S) 6/5/0 (55/45/0) 10/3/0 (77/23/0) 0,247
Vigilance D (A/T/S) 16/4/0 (80/20/0) 17/1/0 (94/6/0) 0,188
Well-being A (E/G/F/P) 0/5/10/5 (0/25/50/25) 0/10/5/2 (0/59/29/12) 0,111
Well-being 5 (E/G/F/P) 0/5/10/5 (0/25/50/25) 1/9/5/2 (6/53/29/12) 0,18
Well-being 15 (E/G/F/P) 0/6/10/4 (0/30/50/20) 0/11/5/1 (0/65/29/6) 0,094
Well-being 30 (E/G/F/P) 0/5/11/4 (0/25/55/20) 0/11/6/0 (0/65/35/0 0,023
Well-being 45 (E/G/F/P) 0/3/10/3 (0/19/62/19) 0/10/6/0 (0/62/38/0) 0,021
Well-being 60 (E/G/F/P) 0/3/8/0 (0/27/73/0) 0/6/6/0 (0/50/50/0) 0,265
Well-being D (E/G/F/P) 0/7/13/0 (0/35/65/0) 0/11/7/0 (0/61/39/0) 0,07
Energy A (N/F/P) 0/5/15 (0/25/75) 3/11/4 (17/61/22) 0,003
Energy 5 (N/F/P) 0/5/15 (0/25/75) 2/12/4 (11/67/22) 0,004
Energy 15 (N/F/P) 0/8/12 (0/40/60) 2/13/3 (11/72/17) 0,014
Energy 30 (N/F/P) 1/8/11 (5/40/55) 2/15/1 (11/83/6) 0,005
Energy 45 (N/F/P) 0/6/10 (0/38/62) 3/14/0 (18/82/0) ≤0,001
Energy 60 (N/F/P) 0/5/6 (0/45/55) 2/11/0 (15/85/0) 0,006
Energy D (N/F/P) 2/9/9 (10/45/45) 3/15/0 (17/83/0) 0,005
All values were recorded at the PACU upon arrival (A), after 5 (5), 15 (15), 30 (30), 45 (45), 60 (60) minutes and at discharge (D). Modified Aldrete scores are given
as mean (SD). Vigilance, Well-being and Energy are shown in total numbers (% of total). Vigilance was distinguished as awake (A), tired (T) or sleeping (S). Well-
being was rated as excellent (E), good (G), fair (F) or poor (P). Energy was classified as normal (N), fair (F) or poor (P).
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Figure 2 TAP. Cognitive function assessed with the TAP. Subtests Alertness (A+B), Divided Attention (C+D), Visual Scanning (E+F), Working
Memory (G+H) and Reaction Change (I+J). Figure pairs show reaction time on the left and valid reactions on the right. All values are Mean
(SEM) and display the change at 6-8 and 66-72 hours normalized to the preoperative baseline. All ordinates are in per cent. Grey lines and open
circles display the xenon group, black lines and open squares represent the sevoflurane group.
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Heavner and colleagues [14]. An earlier time-point
would be preferable, but could not be realized in the
clinical routine.
Considering the time-frame of 12 h for the assessment
(12-24 h preoperatively), we felt that the difference of
39 min between the mean time-points of testing in the
two groups would not have a relevant effect on the
results. Variations in time-points of testing are the con-
sequence of choosing a preoperative time-frame over a
fixed time-point for the assessment. The actual impact
Figure 3 Well-being and Paper-Pencil-Tests. Well-being measured with Bf-S (A) and STAI (B), cognitive function assessed with Paper-Pencil-
Tests DS (C), DSST (D), Trail Making Test A and B (E+F). An increase in percent shows a decline in well-being (A+B) and a decline in outcome
for E and F. A decrease in percent in C and D shows an increase in outcome. All values are Mean (SEM) and display the change at 6-8 and 66-
72 hours normalized to the preoperative baseline. All ordinates are in percent. Grey lines and open circles display the xenon group, black lines
and open squares represent the sevoflurane group.
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can not be quantified, but we suspected a justifiable
benefit from earlier testing.
The power was calculated for the primary outcome
parameter, considering 20% as a relevant difference. As
discussed in previous studies, 10-15% could be a clini-
cally more relevant value [15]. Regarding the secondary
outcome parameters and this consideration, the study
might be underpowered.
The high drop-out rate in the xenon group before the
second postoperative assessment could have further
altered our results.
Sevoflurane was used with an average end-tidal con-
centration of 1.18% (0.2), which is equivalent to 75% of
an age-adapted MAC according to Nickalls and Maple-
son [33]. Xenon was used with a mean concentration of
53% (5.2), resembling 84.1% of a MAC. Since there are
no age-adapted MAC values for xenon available, we pre-
sumed that the used gas concentrations were equivalent.
They match the concentrations used in other studies
[37,38].
The times recorded during recovery of anaesthesia
were significantly faster in the xenon group. This corre-
sponds with the low blood-gas partition coefficient of
xenon (0.115) compared to sevoflurane (0.69) [11]. The
results are similar to those described in earlier studies
[13,15,17,39].
The scores from the PACU were partially in favour of
xenon. The modified Aldrete-scores and the level of
energy were higher in the xenon group throughout the
recorded time-period. These results are comparable with
previous findings [13,15].
The Aldrete-scores were homogenous in both groups
at discharge from the PACU. Self-evaluation of the
anaesthesia showed no difference between patients from
the two groups. Patients’ well-being showed a compar-
able development during the course of the trial (Figure
3).
Conclusions
In conclusion, xenon anaesthesia enables significantly
faster emergence from anaesthesia in the elderly.
No difference in the incidence of POCD could be
detected after xenon and sevoflurane anaesthesia. The
occurrence was comparable in both groups 6-8 and 66-
72 h after the operation.
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